Halozyme Therapeutics
(NASDAQ:HALO)
$38.61
-0.71[-1.81%]
At close: Apr 12
$38.61
0[0.00%]
After Hours: 4:00PM EDT
Consensus Rating1
Overweight
Highest Price Target1
$72.00
Lowest Price Target1
$40.00
Consensus Price Target1
$48.47

Halozyme Therapeutics Stock (NASDAQ:HALO), Analyst Ratings, Price Targets, Predictions

Halozyme Therapeutics Inc has a consensus price target of $48.47, established from looking at the 44 latest analyst ratings. The last 3 analyst ratings were released from TD Cowen, JMP Securities, and HC Wainwright & Co. on February 29, 2024, February 21, 2024, and February 21, 2024. With an average price target of $58.67 between TD Cowen, JMP Securities, and HC Wainwright & Co., there's an implied 51.95% upside for Halozyme Therapeutics Inc from these 3 analyst ratings.

Analyst Trend
2
Oct 23
1
Dec 23
3
1
Jan
2
Feb
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
4.1
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

TD Cowen
JMP Securities
HC Wainwright & Co.
Benchmark
Goldman Sachs

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Halozyme Therapeutics

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
02/29/2024HALOBuy Now
Halozyme Therapeutics
$38.6139.86%TD Cowen
Brendan Smith
→ $54Initiates → OutperformGet Alert
02/21/2024HALOBuy Now
Halozyme Therapeutics
$38.6186.48%JMP Securities
Jason Butler
→ $72ReiteratesMarket Outperform → Market OutperformGet Alert
02/21/2024HALOBuy Now
Halozyme Therapeutics
$38.6129.5%HC Wainwright & Co.
Mitchell Kapoor
$48 → $50MaintainsBuyGet Alert
01/19/2024HALOBuy Now
Halozyme Therapeutics
$38.6129.5%Benchmark
Robert Wasserman
→ $50ReiteratesBuy → BuyGet Alert
01/19/2024HALOBuy Now
Halozyme Therapeutics
$38.6124.32%HC Wainwright & Co.
Mitchell Kapoor
→ $48ReiteratesBuy → BuyGet Alert
01/18/2024HALOBuy Now
Halozyme Therapeutics
$38.6186.48%JMP Securities
Jason Butler
→ $72ReiteratesMarket Outperform → Market OutperformGet Alert
01/18/2024HALOBuy Now
Halozyme Therapeutics
$38.613.6%Goldman Sachs
Graig Suvannavejh
$45 → $40MaintainsNeutralGet Alert
01/18/2024HALOBuy Now
Halozyme Therapeutics
$38.6124.32%HC Wainwright & Co.
Mitchell Kapoor
$61 → $48MaintainsBuyGet Alert
12/26/2023HALOBuy Now
Halozyme Therapeutics
$38.6152.81%Morgan Stanley
Vikram Purohit
$61 → $59MaintainsOverweightGet Alert
10/20/2023HALOBuy Now
Halozyme Therapeutics
$38.6129.5%Benchmark
Robert Wasserman
→ $50ReiteratesBuy → BuyGet Alert
10/19/2023HALOBuy Now
Halozyme Therapeutics
$38.6157.99%HC Wainwright & Co.
Mitchell Kapoor
$60 → $61MaintainsBuyGet Alert
10/09/2023HALOBuy Now
Halozyme Therapeutics
$38.6155.4%HC Wainwright & Co.
Mitchell Kapoor
→ $60ReiteratesBuy → BuyGet Alert
09/08/2023HALOBuy Now
Halozyme Therapeutics
$38.6155.4%HC Wainwright & Co.
Mitchell Kapoor
→ $60ReiteratesBuy → BuyGet Alert
08/30/2023HALOBuy Now
Halozyme Therapeutics
$38.6155.4%HC Wainwright & Co.
Mitchell Kapoor
→ $60ReiteratesBuy → BuyGet Alert
08/15/2023HALOBuy Now
Halozyme Therapeutics
$38.6155.4%HC Wainwright & Co.
Mitchell Kapoor
$61 → $60MaintainsBuyGet Alert
08/10/2023HALOBuy Now
Halozyme Therapeutics
$38.6157.99%Morgan Stanley
Vikram Purohit
$60 → $61MaintainsOverweightGet Alert
07/24/2023HALOBuy Now
Halozyme Therapeutics
$38.6157.99%HC Wainwright & Co.
Mitchell Kapoor
→ $61Initiates → BuyGet Alert
07/24/2023HALOBuy Now
Halozyme Therapeutics
$38.6116.55%Goldman Sachs
Graig Suvannavejh
$43 → $45DowngradeBuy → NeutralGet Alert
05/10/2023HALOBuy Now
Halozyme Therapeutics
$38.6170.94%JMP Securities
Jason Butler
→ $66Reiterates → Market OutperformGet Alert

FAQ

Q

What is the target price for Halozyme Therapeutics (HALO)?

A

The latest price target for Halozyme Therapeutics (NASDAQ: HALO) was reported by TD Cowen on February 29, 2024. The analyst firm set a price target for $54.00 expecting HALO to rise to within 12 months (a possible 39.86% upside). 21 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Halozyme Therapeutics (HALO)?

A

The latest analyst rating for Halozyme Therapeutics (NASDAQ: HALO) was provided by TD Cowen, and Halozyme Therapeutics initiated their outperform rating.

Q

When was the last upgrade for Halozyme Therapeutics (HALO)?

A

The last upgrade for Halozyme Therapeutics Inc happened on May 10, 2023 when Piper Sandler raised their price target to $46. Piper Sandler previously had a neutral for Halozyme Therapeutics Inc.

Q

When was the last downgrade for Halozyme Therapeutics (HALO)?

A

The last downgrade for Halozyme Therapeutics Inc happened on July 24, 2023 when Goldman Sachs changed their price target from $43 to $45 for Halozyme Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Halozyme Therapeutics (HALO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Halozyme Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Halozyme Therapeutics was filed on February 29, 2024 so you should expect the next rating to be made available sometime around February 28, 2025.

Q

Is the Analyst Rating Halozyme Therapeutics (HALO) correct?

A

While ratings are subjective and will change, the latest Halozyme Therapeutics (HALO) rating was a initiated with a price target of $0.00 to $54.00. The current price Halozyme Therapeutics (HALO) is trading at is $38.61, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch